Atai Beckley N.V.ATAIEarnings & Financial Report
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
Revenue
$273.0K
Gross Profit
N/A
Operating Profit
$-25.7M
Net Profit
$-57.3M
Gross Margin
N/A
Operating Margin
-9424.5%
Net Margin
-20993.4%
YoY Growth
58.7%
EPS
$-0.36
Atai Beckley N.V. Q2 FY2024 Financial Summary
Atai Beckley N.V. reported revenue of $273.0K (up 58.7% YoY) for Q2 FY2024, with a net profit of $-57.3M (down 73.5% YoY) (-20993.4% margin).
Key Financial Metrics
| Total Revenue | $273.0K |
|---|---|
| Net Profit | $-57.3M |
| Gross Margin | N/A |
| Operating Margin | -9424.5% |
| Report Period | Q2 FY2024 |
Atai Beckley N.V. Annual Revenue by Year
Atai Beckley N.V. annual revenue history includes year-by-year totals (for example, 2024 revenue was $308.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $308.0K |
| 2023 | $314.0K |
| 2022 | $233.0K |
Atai Beckley N.V. Quarterly Revenue & Net Profit History
Atai Beckley N.V. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $749.0K | +1772.5% | $-61.1M | -8154.1% |
| Q2 FY2025 | $719.0K | +163.4% | $-27.7M | -3856.6% |
| Q1 FY2025 | $1.6M | — | $-26.4M | -1699.7% |
| Q4 FY2024 | $-5.0K | -127.8% | $-39.0M | 779160.0% |
| Q3 FY2024 | $40.0K | -54.0% | $-26.3M | -65715.0% |
| Q2 FY2024 | $273.0K | +58.7% | $-57.3M | -20993.4% |
| Q1 FY2024 | $0 | — | $-26.7M | N/A |
| Q4 FY2023 | $18.0K | -53.8% | N/A | N/A |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18000 | $0 | $273000 | $40000 | $-5000 | $1.6M | $719000 | $749000 |
| YoY Growth | -53.8% | N/A | 58.7% | -54.0% | -127.8% | N/A | 163.4% | 1772.5% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $293.5M | $269.1M | $215.8M | $197.5M | $159.4M | $195.8M | $189.2M | $239.8M |
| Liabilities | $49.2M | $45.9M | $47.2M | $51.2M | $42.8M | $43.5M | $45.3M | $79.9M |
| Equity | $243.0M | $222.5M | $167.9M | $145.7M | $116.3M | $152.1M | $143.7M | $159.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-84.1M | $-22.6M | $-16.2M | $-19.3M | $-24.3M | $-17.8M | $-14.1M | $-23.3M |